Do firms respond to peer disclosures? Evidence from clinical trial disclosures
We examine whether a firm’s decision to disclose non-financial proprietary information depends on peer disclosures of similar information. Using a sample of 5,035 unique clinical trials by U.S. pharmaceutical firms over the 2007-2014 period, we find that the firm is less likely to disclose its own c...
Saved in:
Main Authors: | CAPKUN, Vedran, LOU, Yun, OTTO, Clemens A., WANG, Yin |
---|---|
格式: | text |
語言: | English |
出版: |
Institutional Knowledge at Singapore Management University
2021
|
主題: | |
在線閱讀: | https://ink.library.smu.edu.sg/soa_research/1789 https://ink.library.smu.edu.sg/context/soa_research/article/2816/viewcontent/SSRN_id3344942otto.pdf |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
相似書籍
-
Do firms respond to peer disclosures? Evidence from disclosures of clinical trial results
由: CAPKUN, Vedran, et al.
出版: (2023) -
Consequences of disclosing clinical trial results: Evidence from the food and drug administration amendments act
由: BORVEAU, Thomas, et al.
出版: (2020) -
The effect of mandatory ESG disclosure on firms’ going-private decisions
由: HUANG, Ying-Chi
出版: (2024) -
Regulatory interventions in response to noncompliance with mandatory derivatives disclosure rules
由: BHATTACHARYA, Neil, et al.
出版: (2022) -
Trade secrets law and corporate disclosure: Causal evidence on the proprietary cost hypothesis
由: LI, Yinghua, et al.
出版: (2018)